GlassScriptPhysician profile
Kent Y Chen
NPI 1174623144
$5,303.47
in general payments reported to CMS, 2019-2025
30 companies · $769 in 2025
The $769 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $644 · 2020: $637 · 2021: $510 · 2022: $679 · 2023: $1,031 · 2024: $1,033 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,833.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,655.79 | 2019-2025 | |
| Pfizer INC. | $657.48 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $535.39 | 2019-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $298.80 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $276.53 | 2020-2025 | Eliquis, Camzyos |
| Amgen INC. | $220.28 | 2019-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $210.07 | 2019-2024 | Farxiga, Wainua, Brilinta |
| Bardy Diagnostics, INC. | $200.00 | 2019-2021 | |
| Abbott Laboratories | $176.83 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.60 | 2019-2025 | Jardiance |
| Biosense Webster, INC. | $119.04 | 2020 | |
| Sanofi-Aventis U.S. LLC | $107.69 | 2019-2020 | |
| Novo Nordisk INC | $105.75 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Lexicon Pharmaceuticals, INC. | $87.72 | 2023-2024 | Inpefa |
| Daiichi Sankyo INC. | $57.46 | 2023-2024 | Injectafer |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $47.05 | 2020-2024 | Nexletol |
| Azurity Pharmaceuticals, INC. | $44.27 | 2024-2025 | Edarbyclor, Edarbi |
| Kestra Medical Technology Services, INC. | $43.00 | 2024 | Assure Wcd |
| Tactile Systems Technology INC | $40.61 | 2020-2023 | Flexitouch Plus, Entre Plus |
| Kiniksa Pharmaceuticals International, Plc | $39.68 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $32.53 | 2019-2020 | |
| Scpharmaceuticals INC. | $28.80 | 2023 | |
| Philips North America LLC | $26.48 | 2024 | (Cm9) Amb Mon & Diag Und |
| Alnylam Pharmaceuticals INC. | $22.13 | 2022 | |
| Medicomp INC | $21.01 | 2023 | Telepatch Cardiac Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $17.94 | 2022 | |
| Boston Scientific Corporation | $17.79 | 2024 | Watchman Flx |
| Chiesi USA, INC. | $16.19 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.45 | 2023 | Livalo |
| Kiniksa Pharmaceuticals, LTD. | $15.11 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.